Phase 2 AGA Clinical Trials
18 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–18 of 18 trials
Recruiting
Phase 1Phase 2
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia
Androgenetic alopecia (AGA)Healthy Volunteers - Male and Female
Absci Pty Ltd.227 enrolled4 locationsNCT07317544
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study
Androgenetic alopecia (AGA)
Nanfang Hospital, Southern Medical University76 enrolled1 locationNCT07335367
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+17 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
Androgenetic alopecia (AGA)
Shenzhen People's Hospital388 enrolled1 locationNCT07370519
Recruiting
Phase 2
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Chagas Disease
Novartis Pharmaceuticals130 enrolled19 locationsNCT06632600
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
Androgenetic alopecia (AGA)
Olix Pharmaceuticals, Inc.158 enrolled1 locationNCT07327359
Recruiting
Phase 2
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Advanced Pheochromocytoma and ParagangliomaPCPG
Jazz Pharmaceuticals90 enrolled9 locationsNCT07282587
Recruiting
Phase 2Phase 3
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
Neonatal SepsisPneumoniaInfections+6 more
Minervax ApS338 enrolled6 locationsNCT06592586
Recruiting
Phase 2
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Von Hippel-Lindau DiseasePheochromocytoma/ParagangliomaVon Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma+5 more
José Claudio Casali da Rocha100 enrolled1 locationNCT07167329
Recruiting
Phase 2
Ivonescimab in the Treatment of Multiple Advanced Tumors
Urothelial CarcinomaSarcomaKidney Cancer+16 more
Fudan University400 enrolled1 locationNCT06683846
Recruiting
Phase 2
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Neuroendocrine TumorsParagangliomaPheochromocytoma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS100 enrolled2 locationsNCT06045260
Recruiting
Phase 2
A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)
SyncopeVasovagal Syncope (VVS)
University of Calgary70 enrolled1 locationNCT05755737
Completed
Phase 2
Effects of L-DOPS in Patients with Low- and Normal- Blood Pressure Variants of Orthostatic Intolerance.
Neurally Mediated SyncopeVasovagal Syncope
BakerIDI Heart and Diabetes Institute76 enrolled1 locationACTRN12612000157875